Potential New Therapeutic Approaches for Cisplatin-Resistant Testicular Germ Cell Tumors

Autor(es):Mostrar menos -

Lengert, Andre van Helvoort ; Braga Pereira, Leticia do Nascimento ; Martins Cabral, Eduardo Ramos ; Faria Gomes, Izabela Natalia ; de Jesus, Lais Machado ; Santiago Goncalves, Maria Fernanda ; da Rocha, Aline Oliveira ; Tassinari, Tiago Alexandre ; da Silva, Luciane Sussuchi ; Laus, Ana Carolina ; Vidal, Daniel Onofre ; Pinto, Mariana Tomazini ; Reis, Rui Manuel ; Lopes, Luiz Fernando

• Tipo de documento: Artigo Científico
• Fonte: FRONTIERS IN BIOSCIENCE-LANDMARK; v. 27, n. 8, p. 13-pg., 2022-08-15.

Resumo

Background: Testicular germ cell tumors (TGCTs), a group of heterogeneous neoplasms, are the most frequent tumors of teenagers and young men, with the incidence rising worldwide. High cure rates can be achieved through cisplatin (CDDP)-based treatment, but approximately 10% of patients present refractory disease and virtually no treatment alternatives. Here, we explored new strategies to treat CDDP-resistant. Methods: In vitro TGCT CDDP-resistance model was established and differential mRNA expression profiles were evaluated using NanoString technology. Then, TGCT cell lines were treated with four potential drugs (PCNA-I1, ML323, T2AA, and MG-132) to overcome CDDP-resistance. Results: We found several differentially expressed genes related to DNA repair and cell cycle regulation on CDDP-resistant cell line (NTERA-2R) compared to parental cell line (NTERA-2P), and the proteasome inhibitor MG-132 demonstrated cytotoxic activity in all cell lines evaluated, even at a nanomolar range. MG-132 also enhanced cell lines' sensitivity to CDDP, increasing apoptosis in both NTERA-2P and NTERA-2R. Conclusions: MG-132 emerges as a potential new drug to treat CDDP-resistant TGCT. Targeted therapy based on molecular mechanism insights may contribute to overcome acquired chemotherapy CDDP-resistance. (AU)

• Processo FAPESP: 17/22305-9 - Estudo de biomarcadores de resposta ao cetuximabe e perspectivas do uso de combi-moléculas anti-EGFR em tumores sólidos
• Beneficiário: Izabela Natalia Faria Gomes
• Modalidade de apoio: Bolsas no Brasil - Doutorado